Welcome to the Medical Technology Stock Letter Website

Hulbert Ranking

Peter Brimelow: 'A detailed review of Medical Technology Stock Letter (like the one we did a couple of years ago) reveals real strengths, as borne out by the fact that it's repeatedly been able to pull itself back into Hulbert's top-performing group in the past, through the incredible feat of registering year-on-year triple-digit gains .'

For full article, click here .
By Peter Brimelow,

Investment Scan

DNA Leads the Way

Full article is available only to MTSL subscribers.

Biotech Sector Analysis

Published 7/24/08: DNA in Play?/Big Bios Deliver the Goods
Between the Roche buy-out offer for Genentech and a strong earnings season for Big Bios—during which they have really delivered the goods one after the other—the biotechs have been roaring in a tough market. We are not surprised, but nonetheless also pleased to see the strength spread throughout most of the biotechs, including several of the mid- and smaller-cap names. We have been saying for some time now that Big Bios, their strong revenue potential, and the long patent life on most of their drugs should position them to become market favorites


	Subscribe Now!

	Online subscriptions are now available for instant access to the complete current issue of MTSL. Annual subscribers also receive Special Updates by email, and have access to research tools such as our article archives and company focus pages.

MTSL In The News

Portfolio Performance

August 1 through August 14

Model Portfolio - Down 2.9%
Trader's Portfolio - Down 4.2%

S&P500 - Up 5.5%
Nasdaq - Up 2.0%

MTSL & You
We provide experienced analysis to find sustainable values in the risky field of biotechnology investing. Timely information, clear investment advice, an industry-wide view, and top-rated performance keeps us at the forefront of all investment letters, and makes MTSL the premier tool for biotech investing.

John T. McCamant
Editor

Jim McCamant
Editor at Large

John's Calendar